Literature DB >> 12682812

Prevalence of Tropheryma whipplei DNA in patients with various gastrointestinal diseases and in healthy controls.

L Amsler1, P Bauernfeind, C Nigg, R C Maibach, R Steffen, M Altwegg.   

Abstract

BACKGROUND: Little is known about the epidemiology of Tropheryma whipplei and its prevalence in people without clinical signs of Whipple's disease. PATIENTS AND METHODS: We screened 239 patients with various gastrointestinal diseases for T. whipplei DNA and compared them with 215 healthy controls in order to check whether T. whipplei might be a risk factor for common gastrointestinal problems or diseases. We detected the 16S rDNA of T. whipplei in salivary and stool samples using a specific seminested PCR.
RESULTS: The prevalence of T. whipplei DNA in patients and in controls was 4.2% (95% CI 2.0-7.6% ) and 7.0% (95% CI 4.0-11.3%), respectively. None of the different gastrointestinal diseases was associated with a higher rate of PCR-positive tests, except for the group of patients with reflux syndrome. Five out of 43 patients with reflux were found to be positive, with all five being positive in the salivary sample. This is in contrast to our findings in carriers without reflux with mainly positive stool samples (p < 0.01).
CONCLUSION: We conclude that the asymptomatic carrier state of T. whipplei indeed exists and that it is much more frequent than the rare Whipple's disease. The higher prevalence of T. whipplei DNA in the saliva of patients with reflux syndrome suggests that the stomach might be the habitat of the organism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12682812     DOI: 10.1007/s15010-002-3083-0

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  21 in total

Review 1.  Whipple's disease.

Authors:  Florence Fenollar; Didier Raoult
Journal:  Curr Gastroenterol Rep       Date:  2003-10

2.  Connecting the dots: the many systemic manifestations of whipple disease.

Authors:  Seema Patil; George T Fantry
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-01

Review 3.  Whipple's disease: a macrophage disease.

Authors:  Benoît Desnues; Melanie Ihrig; Didier Raoult; Jean-Louis Mege
Journal:  Clin Vaccine Immunol       Date:  2006-02

4.  Tropheryma whipplei in the environment: survey of sewage plant influxes and sewage plant workers.

Authors:  Maximilian Schöniger-Hekele; Dagmar Petermann; Beate Weber; Christian Müller
Journal:  Appl Environ Microbiol       Date:  2007-02-02       Impact factor: 4.792

5.  Neuro-Whipple confirmed five years after a presumptive diagnosis of a primitive CNS vasculitis.

Authors:  J El Helou; G Saliba; I Kolev; C Pierrot-Deseilligny
Journal:  J Neurol       Date:  2008-05-07       Impact factor: 4.849

6.  An experimental mouse model to establish Tropheryma whipplei as a diarrheal agent.

Authors:  Khatoun Al Moussawi; Nada Malou; Jean-Louis Mege; Didier Raoult; Benoit Desnues
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

Review 7.  Clinical Manifestations, Treatment, and Diagnosis of Tropheryma whipplei Infections.

Authors:  Ruben A V Dolmans; C H Edwin Boel; Miangela M Lacle; Johannes G Kusters
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

8.  Epidemiology of Whipple's Disease in the USA Between 2012 and 2017: A Population-Based National Study.

Authors:  Jamie Ann Elchert; Emad Mansoor; Mohannad Abou-Saleh; Gregory S Cooper
Journal:  Dig Dis Sci       Date:  2018-11-28       Impact factor: 3.199

9.  Tropheryma whipplei in children with gastroenteritis.

Authors:  Didier Raoult; Florence Fenollar; Jean Marc Rolain; Philippe Minodier; Emmanuelle Bosdure; Wenjun Li; Jean Marc Garnier; Herve Richet
Journal:  Emerg Infect Dis       Date:  2010-05       Impact factor: 6.883

10.  Use of genome selected repeated sequences increases the sensitivity of PCR detection of Tropheryma whipplei.

Authors:  Florence Fenollar; Pierre-Edouard Fournier; Catherine Robert; Didier Raoult
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.